About: Anti‐inflammatory and antiviral roles of hydrogen sulfide: rationale for considering H(2)S‐donors in COVID‐19 therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Anti‐inflammatory and antiviral roles of hydrogen sulfide: rationale for considering H(2)S‐donors in COVID‐19 therapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Anti‐inflammatory and antiviral roles of hydrogen sulfide: rationale for considering H(2)S‐donors in COVID‐19 therapy
Creator	Calderone, Vincenzo Brancaleone, Vincenzo Brogi, Simone Citi, Valentina Gojon, Gabriel Martelli, Alma Montanaro, Rosangela Morales, Guillermo Testai, Lara
topic	covid:507f63f1e8f6f2c53bfc6ddf8720c9e8acb0c8fc#this
Source	Medline; PMC
abstract	The COVID‐19 pandemic caused by new betacoronavirus SARS‐Cov‐2 demands rapid exploration of safe and effective therapeutic options. In this perspective, “drug repurposing” aims to represent a rapid and valuable strategy. In the last decades, the endogenous gasotransmitter hydrogen sulfide (H(2)S) has emerged as a ubiquitous modulator of several biological functions. Early studies pointed out its importance in the regulation of numerous biological functions and systems. Accordingly, H(2)S deficiency has been associated with several disorders, and many chemotypes of H(2)S‐releasing agents have been developed as potential therapeutic tools for diseases related with impaired H(2)S production/activity. Some of these compounds are in advanced clinical trials. Presently, the pivotal role of H(2)S in modulating the inflammatory response and proinflammatory cytokine cascade is well recognized, and the usefulness of some H(2)S‐donors for the treatment of different forms of acute lung inflammation (due to infectious and non‐infectious etiologies) has been reported. More recent evidence is also unravelling several mechanisms of action which may account for antiviral effects of this gasotransmitter. Noteworthy, some preliminary clinical results suggest an inverse relationship between endogenous H(2)S levels and severity of COVID‐19 disease. Therefore, repurposing of H(2)S‐releasing drugs may be worthy of investigation as potential therapeutic opportunities for treatment of COVID‐19 disease.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.1111/bph.15230
bibo:pmid	32783196
has license	no-cc
sha1sum (hex)	507f63f1e8f6f2c53bfc6ddf8720c9e8acb0c8fc
schema:url	https://doi.org/10.1111/bph.15230
resource representing a document's title	Anti‐inflammatory and antiviral roles of hydrogen sulfide: rationale for considering H(2)S‐donors in COVID‐19 therapy
has PubMed Central identifier	PMC7436626
has PubMed identifier	32783196
schema:publication	Br J Pharmacol
resource representing a document's body	covid:507f63f1e8f6f2c53bfc6ddf8720c9e8acb0c8fc#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/507f63f1e8f6f2c53bfc6ddf8720c9e8acb0c8fc
is schema:about of	named entity 'systems' named entity 'COVID-19' named entity 'gasotransmitter' named entity 'disease' named entity 'modulator' named entity 'action' named entity 'therapeutic' named entity 'antiviral' named entity 'DISORDERS' named entity 'EVIDENCE' named entity 'DISEASE' named entity 'EFFECTIVE' named entity 'CLINICAL TRIALS' named entity 'LUNG INFLAMMATION' named entity 'DIFFERENT' named entity 'FORMS' named entity 'BIOLOGICAL FUNCTIONS' named entity 'DONORS' named entity 'SARS-COV-2' named entity 'RELEASING' named entity 'INFECTIOUS' covid:arg/507f63f1e8f6f2c53bfc6ddf8720c9e8acb0c8fc named entity 'potential' named entity 'opportunities' named entity 'activity' named entity 'H2S' named entity 'cascade' named entity 'numerous' named entity 'agents' named entity 'rapid' named entity 'strategy' named entity 'production' named entity 'betacoronavirus' named entity 'perspective' named entity 'tools' named entity 'hydrogen sulfide' named entity 'proinflammatory cytokine' named entity 'etiologies' named entity 'H2S' named entity 'gasotransmitter' named entity 'endogenous' named entity 'COVID-19 disease' named entity 'inflammatory response' named entity 'H2S' named entity 'endogenous' named entity 'COVID-19 pandemic' named entity 'mechanisms of action' named entity 'antiviral' named entity 'hydrogen sulfide' named entity 'lung' named entity 'anti-inflammatory' named entity 'coagulative' named entity 'proinflammatory' named entity 'antiviral' named entity 'Sulfane' named entity 'molecular mechanism' named entity 'anti-inflammatory' named entity 'viral replication' named entity 'H2S' named entity 'mouse model' named entity 'neutrophil' named entity 'cysteine' named entity 'lung disease' named entity 'H2S' named entity 'disulfide' named entity 'hydrogen atom' named entity 'disulphide bonds' named entity 'host cells' named entity 'low-grade' named entity 'Hydrogen sulfide' named entity 'exogenous'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software